Clinical trials
Terminated Multiple Sclerosis trials in the United States
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
99 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 1 |
| 2003 | 2 |
| 2004 | 2 |
| 2006 | 1 |
| 2007 | 3 |
| 2008 | 6 |
| 2009 | 3 |
| 2010 | 6 |
| 2011 | 3 |
| 2012 | 3 |
| 2013 | 6 |
| 2014 | 4 |
| 2015 | 5 |
| 2016 | 6 |
| 2017 | 8 |
| 2018 | 6 |
| 2019 | 8 |
| 2020 | 3 |
| 2021 | 11 |
| 2022 | 7 |
| 2023 | 1 |
| 2024 | 3 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Terminated | 99 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Biogen | 11 |
| EMD Serono | 4 |
| NYU Langone Health | 4 |
| National Institute of Neurological Disorders and Stroke (NINDS) | 3 |
| Bristol-Myers Squibb | 2 |
| Institute for Neurodegenerative Disorders | 2 |
| Jazz Pharmaceuticals | 2 |
| National Institute of Allergy and Infectious Diseases (NIAID) | 2 |
| Novartis Pharmaceuticals | 2 |
| Oregon Health and Science University | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Multiple Sclerosis | 99 |
| Multiple Sclerosis, Relapsing-Remitting | 11 |
| Muscle Spasticity | 6 |
| Parkinson Disease | 5 |
| Autoimmune Diseases | 4 |
| Fatigue | 4 |
| Multiple Sclerosis, Chronic Progressive | 4 |
| Stroke | 4 |
| Alzheimer Disease | 3 |
| Arthritis, Rheumatoid | 3 |
Trials
Showing 1 to 25 of 99. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.